Neuphoria Therapeutics Q4 EPS $(0.95) Misses $(0.56) Estimate, Sales $1.174M.

Neuphoria Therapeutics (NASDAQ: NEUP) reported Q4 earnings with a loss of $(0.95) per share, missing the analyst estimate of $(0.56) by 69.64%. This represents a 76.13% improvement over the $(3.98) loss per share reported in the same quarter last year. The company generated $1.174 million in sales during this period.